Long‐term prognosis and clinical practice for new‐onset ulcerative colitis in the era of biologics: A Japanese retrospective study

Abstract

AbstractBackground and AimThere is a scarcity of data on long‐term outcomes in patients with new‐onset ulcerative colitis (UC) in the era of biologics. We aimed to clarify the long‐term prognosis of UC and the clinical practice of prescriptions for UC.MethodsWe collected 6689 new‐onset UC cases using a medical claim database provided by DeSC Healthcare, Inc. We investigated the surgery‐free, systemic steroid‐free, and molecular targeting drug‐free rates and compared their differences based on UC‐onset age. We used multivariate analysis to identify clinical factors affecting long‐term prognosis and investigated the transition of prescriptions for UC.ResultsThe surgery‐free, systemic steroid‐free, and molecular targeting drug‐free rates at 5 years post‐UC diagnosis were 98.5%, 61.0%, and 88.7%, respectively. Pediatric patients had higher surgery‐free rates compared with elderly patients and non‐pediatric/non‐elderly patients (P = 0.022), whereas the systemic steroid‐free and molecular targeting drug‐free rates were significantly lower (P< 0.0001, P < 0.0001, respectively). The retention rate of the first molecular targeting drug did not differ between drugs. The prescription rates of systemic steroid, immunomodulator, and molecular targeting drug increased from the second quarter in 2014 to the fourth quarter in 2021 (29.8%–39.1%, 6.8%–17.7%, and 7.6%–16.4%, respectively).ConclusionsWe clarified the long‐term prognosis and clinical practice of new‐onset UC cases. The long‐term outcome after UC onset might improve because of increasing use of new therapeutic agents. Further investigations are warranted.